US 12,390,456 B2
Pridopidine for treating Huntington's disease
Merav Bassan, Netanya (IL); Esther Lukasiewicz Hagai, Tel Aviv (IL); Eli Eyal, Petah-Tikva (IL); and Anna Kristina Sveinsdotter Teige Wickenberg, Lund (SE)
Assigned to Prilenia Neurotherapeutics Ltd., Yakum (IL)
Filed by PRILENIA NEUROTHERAPEUTICS LTD., Herzliya (IL)
Filed on Jun. 20, 2021, as Appl. No. 17/352,305.
Application 17/352,305 is a continuation of application No. 16/438,508, filed on Jun. 12, 2019, granted, now 11,090,297.
Application 16/438,508 is a continuation in part of application No. 14/309,111, filed on Jun. 19, 2014, granted, now 10,322,119.
Claims priority of provisional application 61/877,832, filed on Sep. 13, 2013.
Claims priority of provisional application 61/837,928, filed on Jun. 21, 2013.
Prior Publication US 2021/0308115 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/451 (2006.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/451 (2013.01) [A61K 9/0053 (2013.01); A61P 25/28 (2018.01)] 9 Claims
 
1. A method of reducing impairment of functional capacity of a human patient afflicted with Huntington's disease, consisting essentially of orally administering to the human patient a pharmaceutical composition comprising only pridopidine or a pharmaceutically acceptable salt thereof as the active ingredient, thereby reducing impairment of functional capacity of the human patient.